Lucinactant

Summary

Lucinactant (brand name Surfaxin) is a synthetic pulmonary surfactant containing the sinapultide (KL4) peptide, phospholipids, and fatty acids. It is FDA-approved for the prevention of respiratory distress syndrome (RDS) in premature infants. It is the first fully synthetic surfactant approved in the US, offering an alternative to animal-derived surfactants.

Mechanism of Action

Lucinactant contains sinapultide (KL4 peptide), a synthetic peptide that mimics the hydrophobic surfactant protein B (SP-B). It reduces alveolar surface tension at the air-liquid interface, stabilizing alveoli and preventing collapse during expiration, thereby improving lung compliance and gas exchange in premature infants.

Routes of Administration

Goals & Uses

• Prevention of Respiratory Distress Syndrome (RDS)Neonatal PulmonologyHigh
• Improvement of lung compliance in premature infantsRespiratory SupportHigh
• Treatment of established RDSNeonatal PulmonologyModerate
• Aerosolized surfactant delivery (investigational)Drug Delivery InnovationLow

Contraindications

• Use in non-premature or term infants without surfactant deficiencyIndication MismatchModerate
• Known hypersensitivity to lucinactant or any componentAllergyHigh

Adverse Effects

• Endotracheal tube blockage or refluxProceduralUncommon
• Oxygen desaturationPulmonaryCommon
• Pallor or cyanosisCardiovascular/RespiratoryCommon
• Pulmonary hemorrhagePulmonaryUncommon
• BradycardiaCardiovascularCommon

Drug Interactions

• Inhaled nitric oxideLow

Population Constraints

• Infants with active infection or sepsisConcurrent IllnessRelative
• Premature neonates (primary population)Age/developmentalAbsolute
• Infants with congenital anomalies affecting lung developmentStructural AnomalyRelative

Regulatory Status

• European UnionUnapprovedNot approved by EMA as of available data; animal-derived surfactants are standard of care in Europe.
• United StatesApprovedApproved: Prevention of Respiratory Distress Syndrome (RDS) in premature infants at high risk for RDSFDA approved March 6, 2012 (NDA 21-746). First fully synthetic surfactant approved in the US. Manufactured by Discovery Laboratories/Windtree Therapeutics.
• United KingdomUnapprovedNot approved by MHRA; poractant alfa and beractant are predominant options in the UK.

Approved by the FDA in March 2012 for prevention of RDS in premature infants at high risk. Manufactured by Discovery Laboratories. The liquid formulation (Aerosurf) for aerosolized delivery was under investigation but development challenges were reported.

Evidence & Sources

No sources recorded yet.